MA53636A - AGENT FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS - Google Patents

AGENT FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS

Info

Publication number
MA53636A
MA53636A MA053636A MA53636A MA53636A MA 53636 A MA53636 A MA 53636A MA 053636 A MA053636 A MA 053636A MA 53636 A MA53636 A MA 53636A MA 53636 A MA53636 A MA 53636A
Authority
MA
Morocco
Prior art keywords
agent
treatment
dermatological disorders
dermatological
disorders
Prior art date
Application number
MA053636A
Other languages
French (fr)
Inventor
Laura Calzà
Bruno Pietro Imbimbo
Gino Villetti
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MA53636A publication Critical patent/MA53636A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/48Nerve growth factor [NGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/185Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
MA053636A 2018-09-17 2019-09-17 AGENT FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS MA53636A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18194930 2018-09-17
EP18203665 2018-10-31

Publications (1)

Publication Number Publication Date
MA53636A true MA53636A (en) 2021-12-22

Family

ID=67989007

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053636A MA53636A (en) 2018-09-17 2019-09-17 AGENT FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS

Country Status (11)

Country Link
US (1) US20220064243A1 (en)
EP (1) EP3852785A1 (en)
JP (1) JP2022502359A (en)
KR (1) KR20210061388A (en)
CN (1) CN113226350A (en)
AU (1) AU2019343514A1 (en)
BR (1) BR112021003820A2 (en)
CA (1) CA3111158A1 (en)
MA (1) MA53636A (en)
MX (1) MX2021002983A (en)
WO (1) WO2020058217A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023536229A (en) * 2020-07-27 2023-08-24 ヒューマン セル カンパニー NGF variants, production, compositions and therapeutic uses
EP4274546A1 (en) * 2021-01-06 2023-11-15 The Penn State Research Foundation Methods and materials for treating hair loss

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE257514T1 (en) 1998-10-09 2004-01-15 Scil Proteins Gmbh METHOD FOR OBTAINING ACTIVE BETA-NGF
WO2003075949A1 (en) 2002-03-12 2003-09-18 Bio-Click Technologies Ltd. Method and composition for treating skin wounds with epidermal growth factor
ITRM20060367A1 (en) 2006-07-13 2008-01-14 Lay Line Genomics Spa HNGF MUTEIN THERAPEUTIC USES AND PHARMACEUTICAL COMPOSITIONS
WO2010128519A1 (en) 2009-05-04 2010-11-11 Kumar C Jairaj A method for detecting neuropathy and predicting foot ulcer development in human beings with health conditions like diabetes mellitus
HUE027245T2 (en) 2011-12-19 2016-10-28 Wacker Chemie Ag Novel prongf mutants and uses thereof in the production of beta-ngf
US20180086805A1 (en) * 2016-05-20 2018-03-29 Chiesi Farmaceutici S.P.A. proNGF mutants and uses thereof for the preparation of NGF mutants

Also Published As

Publication number Publication date
CN113226350A (en) 2021-08-06
BR112021003820A2 (en) 2021-05-25
AU2019343514A1 (en) 2021-04-15
US20220064243A1 (en) 2022-03-03
KR20210061388A (en) 2021-05-27
JP2022502359A (en) 2022-01-11
EP3852785A1 (en) 2021-07-28
MX2021002983A (en) 2021-05-14
CA3111158A1 (en) 2020-03-26
WO2020058217A1 (en) 2020-03-26

Similar Documents

Publication Publication Date Title
DK3731772T3 (en) SYSTEMS FOR THE TREATMENT OF DISEASE STATES AND DISORDERS
MA45481A (en) USE OF EXOSOMES FOR THE TREATMENT OF DISEASES
MA51200A (en) NEW COMPOUNDS AND ASSOCIATED PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISEASES
MA51673A (en) COMPOUNDS INTENDED FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS
MA52575A (en) DRESSING FOR THE TREATMENT OF DAMAGED SKIN
MA44875A (en) COMPOSITIONS FOR THE TREATMENT OF ACID BASIC DISORDERS
FR3046933B1 (en) NLRP3 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS
MA47719A (en) ESKETAMINE FOR THE TREATMENT OF DEPRESSION
IL279260A (en) Kdm1a inhibitors for the treatment of disease
MA51139A (en) 1- (PIPERIDINOCARBONYLMETHYL) -2-OXOPIPERAZINE DERIVATIVES FOR THE TREATMENT OF CANCER
MA44737A (en) COMPOSITIONS FOR THE TREATMENT OF DISORDERS RELATED TO HYPERKERATOSIS
MA42953A (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISORDERS
MA47207A (en) COMPOUNDS USEFUL FOR THE TREATMENT OF DIGESTIVE TRACT DISORDERS
MA49141A (en) PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR THE TREATMENT OF SKIN CONDITIONS
MA51672A (en) COMPOUNDS INTENDED FOR THE TREATMENT OF KINASIS-DEPENDENT DISORDERS
MA52761A (en) DOSAGE REGIMEN FOR THE TREATMENT OF PI3K-RELATED DISORDERS
MA51738A (en) COMPOUNDS FOR THE TREATMENT OF PAIN
MA54077A (en) POLYTHERAPY FOR THE TREATMENT OF BLOOD DISEASES
MA43800A (en) ORAL OCTREOTIDE FOR THE TREATMENT OF DISEASES
MA53741A (en) METHODS OF TREATING MYELOPROLIFERATIVE DISORDERS
MA39927A (en) GLYT1 INHIBITORS FOR THE TREATMENT OF BLOOD DISORDERS
MA50391A (en) NEW COMPOUNDS AND ASSOCIATED PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY DISORDERS
MA47212A (en) TREATMENT METHODS FOR NEUROLOGICAL DISORDERS
MA46099A (en) COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION
MA43825A (en) DOSAGE SCHEDULES FOR THE TREATMENT OF FUNGAL INFECTIONS